Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
Intestinal fibrosis is a common complication of inflammatory bowel disease. So far, there is no safe and effective drug for intestinal fibrosis. Pirfenidone is an anti-fibrotic compound available for the treatment of idiopathic pulmonary fibrosis. Here, we explored the anti-proliferative and anti-fibrotic properties of pirfenidone on primary human intestinal fibroblasts (p-hIFs). p-hIFs were cultured in the absence and presence of pirfenidone. Cell proliferation was measured by a real-time cell analyzer (xCELLigence) and BrdU incorporation. Cell motility was monitored by live cell imaging. Cytotoxicity and cell viability were analyzed by Sytox green, Caspase-3 and Water Soluble Tetrazolium Salt-1 (WST-1) assays. Gene expression of fibrosis markers was determined by quantitative reverse transcription PCR (RT-qPCR). The mammalian target of rapamycin (mTOR) signaling was analyzed by Western blotting and type I collagen protein expression additionally by immunofluorescence microscopy. Pirfenidone dose-dependently inhibited p-hIF proliferation and motility, without inducing cell death. Pirfenidone suppressed mRNA levels of genes that contribute to extracellular matrix production, as well as basal and TGF-β1-induced collagen I protein production, which was associated with inhibition of the rapamycin-sensitive mTOR/p70S6K pathway in p-hIFs. Thus, pirfenidone inhibits the proliferation of intestinal fibroblasts and suppresses collagen I production through the TGF-β1/mTOR/p70S6K signaling pathway, which might be a novel and safe anti-fibrotic strategy to treat intestinal fibrosis.
Cyclooxygenase‑2 (COX‑2) and interleukin‑32 (IL‑32) expression has been examined in various carcinomas and inflammations, and has been suggested to be significant in tumor progression and prognosis. The present study was conducted to investigate the expression of COX‑2 and IL‑32 in primary gastric B‑cell lymphoma in order to define their clinical significance and their association with Helicobacter pylori (Hp) infection. COX‑2 and IL‑32 protein expression was detected in 31 primary gastric B‑cell lymphoma patients and 19 chronic gastritis patients with immunohistochemistry. COX‑2 and IL‑32 expression was significantly higher in primary gastric lymphoma (PGL) tissues compared with gastritis tissues (51.6 vs. 21.1% for COX‑2, P=0.032; and 58.1 vs. 26.3% for IL‑32, P=0.029) and was significantly higher in Hp+ lymphoma tissues compared with Hp‑ lymphoma tissues (66.7 vs. 20% for COX‑2, P=0.015; and 71.4 vs. 30% for IL‑32, P=0.029). In the PGL tissues, the expression level of COX‑2 was positively correlated with the expression level of IL‑32, and the two were each positively correlated with Hp infection (P=0.004 for COX‑2 and IL‑32; P=0.01 for COX‑2 and Hp infection; and P=0.003 for IL‑32 and Hp infection). COX‑2 expression was found to be significantly associated (P<0.05) with an aggressive tumor type, higher expression of Ki‑67, frequent lymph node metastasis and advanced stage. IL‑32 expression was found to be significantly correlated (P<0.05) with frequent lymph node metastasis and an advanced stage. The survival time was longer in the COX‑2‑ and IL‑32‑ lymphoma patients compared with the COX‑2+ and IL‑32+ lymphoma patients, but these differences were not statistically significant. These results suggested that Hp infection and the expression of COX‑2 and IL‑32 were closely linked with each other, and that the overexpression of COX‑2 and IL‑32 was correlated with tumor progression in primary gastric B‑cell lymphoma, thus indicating potential novel therapeutic target.